5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
NEUTRAL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 8.54▲ | 8.53▲ | 8.53▲ | 8.68▲ | 9.15▼ |
MA10 | 8.57▲ | 8.58▲ | 8.58▲ | 8.69▲ | 9.45▼ |
MA20 | 8.60▲ | 8.72▼ | 8.72▼ | 9.04▼ | 10.94▼ |
MA50 | 8.92▼ | 9.19▼ | 9.23▼ | 9.49▼ | 10.93▼ |
MA100 | 9.37▼ | 9.48▼ | 9.51▼ | 11.12▼ | 12.81▼ |
MA200 | 9.56▼ | 9.59▼ | 9.96▼ | 11.14▼ | 12.95▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.014▲ | 0.012▲ | 0.013▲ | 0.028▲ | -0.226▼ |
RSI | 44.768▼ | 41.464▼ | 41.245▼ | 46.368▼ | 36.786▼ |
STOCH | 27.778 | 32.288 | 32.288 | 38.770 | 20.010 |
WILL %R | -33.333 | -41.176 | -41.176 | -38.057 | -84.836▼ |
CCI | 0.484 | -8.347 | -8.347 | 24.591 | -111.110▼ |
Thursday, April 25, 2024 01:41 PM
US pharma giant Merck & Co (NYSE: MRK) raised and narrowed its forecasts for profit and sales for 2024 in presenting its first-quarter 2024 financial results.
|
Thursday, April 25, 2024 11:54 AM
MRK stock results show that Merck & Co beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.More From InvestorPlace The #1 AI Investment Might Be This ...
|
Thursday, April 25, 2024 09:29 AM
U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion. Excluding the impact of foreign exchange ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
25/04/24 | 8.7156 | 9.10 | 8.70 | 9.02 | 6,590 |
24/04/24 | 8.27 | 8.9504 | 8.27 | 8.95 | 27,054 |
23/04/24 | 8.55 | 8.64 | 8.40 | 8.40 | 4,121 |
22/04/24 | 8.51 | 8.67 | 8.51 | 8.52 | 3,460 |
19/04/24 | 8.65 | 9.00 | 8.51 | 8.51 | 23,104 |
18/04/24 | 8.27 | 8.70 | 8.27 | 8.43 | 9,362 |
17/04/24 | 8.74 | 8.86 | 8.255 | 8.36 | 6,583 |
16/04/24 | 9.1897 | 9.1897 | 8.61 | 8.74 | 4,174 |
15/04/24 | 9.01 | 9.185 | 8.70 | 8.90 | 8,608 |
12/04/24 | 9.00 | 9.1899 | 8.8601 | 9.08 | 7,054 |
|
|
||||
|
|
||||
|
|